The Eplontersen Pregnancy and Lactation Outcomes Study

NCT07205666 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2026-05-01

No results posted yet for this study

Summary

The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant associated with exposure to eplontersen during pregnancy and/or lactation.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Myriam Alexander, PHD · AstraZeneca

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2035-12-30
Completion
2035-12-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07205666 on ClinicalTrials.gov